Dissecting the underlying mechanism in vitro, Fukushima et al. showed that glasdegib reduces the LSC-containing CD34+CD38− population and increases the proliferative cell fraction in patient-derived AML samples. This evidence concerns the gene CD38 and acute myeloid leukemia.